title: New drugs and devices in the pipeline for heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction.
abstract: Heart failure (HF) is a growing problem in the USA and other industrialized nations. HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) each make up approximately half of the overall HF burden. Although a variety of medical and surgical therapies exist for the treatment of patients with HFrEF, morbidity and mortality remain high, and cardiac transplantation, considered the current gold standard for patients with HFrEF and severe symptoms, is reserved for relatively few eligible patients. Patients with HFpEF have more limited therapeutic options, because no medical therapy to date has been shown to improve survival in these patients. With the rising prevalence of HF and its increasing role in health care expenditure, there is a substantial need for new drug and device therapies for HFrEF and, in particular, HFpEF. This forms the topic of the current review.
authors.affiliation: Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, USA, araina@wpahs.org.
authors.forename: Amresh
authors.initials: A
authors.lastname: Raina
authors.forename: Manreet
authors.initials: M
authors.lastname: Kanwar
mesh_terms: D004059:Diffusion of Innovation; D006333:Heart Failure / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D013318:Stroke Volume / Q000502:physiology*